Home > Insider Trading > Filing (0000921895-19-001055)

Filing Details

Accession Number:: 0000921895-19-001055
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-09 18:30:52
Reporting Period:: 2019-04-05

Accepted Time:: 2019-04-09 18:30:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1626392	Jfl Partners Fund Lp	2110 Ranch Road 620S #341732 Lakeway TX 78734	No	No	Yes	Yes
1687888	Jfl Capital Management, Llc	2110 Ranch Road 620 S 341732 Lakeway TX 78734	No	No	Yes	Yes
1770400	Jfl Capital Management Lp	2110 Ranch Road 620 S, #341732 Lakeway TX 78734	No	No	Yes	Yes
1770401	F. Joseph Lawler	2110 Ranch Road 620 S, #341732 Lakeway TX 78734	No	No	Yes	Yes
1770405	Jfl Capital Holdings Llc	2110 Ranch Road 620 S, #341732 Lakeway TX 78734	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-05	26,288	$5.95	703,524	No	4	P	Indirect	By: Managed Account of JFL Capital Management LLC
Common Stock	Acquisiton	2019-04-08	6,484	$5.73	710,008	No	4	P	Indirect	By: Managed Account of JFL Capital Management LLC
Common Stock	Acquisiton	2019-04-08	4,506	$5.73	489,532	No	4	P	Indirect	By: JFL Partners Fund LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By: Managed Account of JFL Capital Management LLC
No	4	P	Indirect	By: Managed Account of JFL Capital Management LLC
No	4	P	Indirect	By: JFL Partners Fund LP

Footnotes

This Form 4 is filed jointly by JFL Partners Fund LP ("JFL Partners"), JFL Capital Management LP ("JFL GP"), JFL Capital Holdings LLC ("JFL Holdings"), JFL Captal Management LLC ("JFL Capital Management") and Joseph F. Lawler (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by JFL Partners. As the general partner of JFL Partners, JFL GP may be deemed to beneficially own the securities owned directly by JFL Partners. As the general parter of JFL GP, JFL Holdings may be deemed to beneficially own the securities owned directly by JFL Partners. JFL Capital Management, as the investment manager of JFL Partners, may be deemed to beneficially own the securities owned directly by JFL Partners. Dr. Lawler, as the managing member of both JFL Holdings and JFL Capital Management, may be deemed to beneficially own the securities owned directly by JFL Partners.
Securities held in an account separately managed by JFL Capital Management (the "JFL Managed Account"). JFL Capital Management, as the investment manager of the JFL Managed Account, may be deemed to beneficially own the securities held in the JFL Managed Account. Dr. Lawler, as the managing member of JFL Capital Management, may be deemed to beneficially own the securities held in the JFL Managed Account.
The reported price in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $5.9501 to $6, excluding commissions. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $5.7113 to $5.7462, excluding commissions. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth in this footnote.